{"id":"NCT00338286","sponsor":"Janssen Research & Development, LLC","briefTitle":"A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy","officialTitle":"A Randomized, Open-label, Multicenter, Phase 3 Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-03-02","primaryCompletion":"2014-07-07","completion":"2017-01-31","firstPosted":"2006-06-20","resultsPosted":"2016-03-24","lastUpdate":"2018-03-19"},"enrollment":2098,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Breast Cancer","Neoplasm Metastasis"],"interventions":[{"type":"OTHER","name":"Standard supportive care (packed RBC transfusion)","otherNames":[]},{"type":"DRUG","name":"epoetin alfa + packed RBC transfusion","otherNames":[]}],"arms":[{"label":"001","type":"EXPERIMENTAL"},{"label":"002","type":"OTHER"}],"summary":"The purpose of this study is to assess the impact on tumor progression as evaluated by progression-free survival (PFS) of epoetin alfa plus standard supportive care as compared with standard supportive care alone (packed red blood cell (RBC) transfusions), for treating anemia according to label guidance in patients with metastatic breast cancer receiving standard chemotherapy.","primaryOutcome":{"measure":"Progression Free Survival","timeFrame":"From the date of randomization to the date of disease progression (PD) or death, whichever occurred first (up to 8.4 years)","effectByArm":[{"arm":"Standard of Care (SOC)","deltaMin":7.4,"sd":null},{"arm":"Epoetin Alfa","deltaMin":7.4,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":9,"exclusionCount":11},"locations":{"siteCount":174,"countries":["United States","Argentina","Brazil","Bulgaria","Chile","Colombia","Ecuador","Georgia","Hong Kong","India","Indonesia","Malaysia","Mexico","North Macedonia","Philippines","Poland","Romania","Russia","South Africa","Taiwan","Ukraine"]},"refs":{"pmids":["26858335"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":229,"n":1045},"commonTop":["Neutropenia","Alopecia","Leukopenia","Nausea","Fatigue"]}}